Highest-materiality recent filing
Core Laboratories director Kwaku Temeng resigns Oct 1 over strategy, governance disagreement
Kwaku Temeng resigns as director effective Oct 1, 2026; cites disagreement over strategic direction and governance.
Core Labs Q2 revenue $124.6M, down 4% YoY; EPS ex-items $0.11, down 42% YoY; declares $0.01 dividend
Revenue $124.6M, up 2% sequentially but down 4% YoY; GAAP EPS $0.13, ex-items EPS $0.11.
Core Labs shareholders re-elect directors, ratify auditor, approve say-on-pay at May 12 meeting
Re-elected Harvey Klingensmith (35.9M for, 3.8M withheld) and Curtis Anastasio (39.3M for, 0.4M withheld) as Class I directors.
Core Lab Q1 revenue $121.8M; GAAP EPS -$0.02, ex-items $0.06
Revenue $121.8M, down 12% sequentially and flat year-over-year.
Core Labs cuts Q1 2026 guidance citing Middle East conflict; revenue now $119-123M
First quarter 2026 revenue guidance revised to $119M-$123M, down from previously issued guidance.
Core Laboratories corrects Q4/FY2025 tax error; net income down $4.2M, EPS down $0.09
Income tax expense understated by $4.2M in Q4 and FY2025 due to tax reconciliation and fire-related insurance gain timing.
Board approved amendment reducing supermajority voting requirement from 66-2/3% to simple majority for certain shareholder actions including mergers and change-in-control.
Core Lab Q4 rev $138.3M (+7% YoY); ex-items EPS $0.21 (-4%); declares $0.01 dividend
Q4 revenue $138.3M (+7% YoY); GAAP EPS $0.15, ex-items $0.21 (-4% YoY).
Core Labs Q3 rev $134.5M flat YoY; ex-items EPS $0.22, down 12% YoY
Revenue $134.5M, up 3% sequentially but flat YoY.
Core Lab Q2 rev $130.2M (+5% seq, flat YoY); ex-items EPS $0.19; free cash flow $10.4M
Q2 revenue $130.2M (+5% sequentially, flat YoY); GAAP EPS $0.22; ex-items EPS $0.19 (-14% YoY, +33% sequentially).
Core Labs elects three Class II directors, ratifies KPMG, approves say-on-pay
Elected Martha Z. Carnes, Katherine Murray, and Rob Martinovich as Class II directors to serve until 2028.
Core Labs Q1 rev $123.6M, ex-items EPS $0.14 down 25% YoY, declares $0.01 dividend
Revenue $123.6M, down 4% sequentially and 5% YoY; GAAP EPS $0.00, ex-items EPS $0.14 (down 25% YoY).
Core Lab Q4 revenue $129.2M, EPS $0.15; FY revenue $523.8M up 3%, free cash flow $43.4M up 200%
Q4 2024 revenue $129.2M (down 4% sequentially, up slightly YoY); GAAP EPS $0.15; ex-items EPS $0.22 (down 12% sequentially, up 16% YoY).
Core Lab Q3 revenue $134.4M +7% YoY; EPS ex-items $0.25 +14% YoY; net debt reduced
Revenue $134.4M, up 3% sequentially and over 7% year-over-year.
Revenue $130.6M, up slightly sequentially and YoY; operating income GAAP $16.0M, ex-items $16.4M (+10% sequentially, +5% YoY).
Annual meeting results: all four proposals approved by shareholders
Class III directors Lawrence Bruno and Kwaku Temeng re-elected with 37.4M and 33.0M votes for respectively.
Core Laboratories Q1 2024: Revenue $129.6M, EPS ex-items $0.19; declares $0.01 dividend
Q1 2024 revenue $129.6M, up modestly sequentially and YoY.
Core Laboratories appoints Sow Hang Teo as VP & CAO after Kevin Daniels resigns
Kevin Daniels resigned as VP & Chief Accounting Officer effective March 21, 2024; departure not due to dispute over accounting practices or financials.
Core Laboratories amends Q4 2023 results; net income cut by $4.3M on tax error
Q4 2023 GAAP net income restated to $2.2M from $6.5M; diluted EPS revised to $0.05 from $0.14.
Core Lab Q4 revenue $128.2M (+2% seq); EPS ex-items $0.19 (-14% seq); FY EPS +40%
Q4 revenue $128.2M (+2% sequentially); GAAP EPS $0.14, ex-items EPS $0.19 (down 14% seq).
Core Lab Q3 revenue $125.3M, EPS $0.19 GAAP ($0.22 ex-items); $0.01 dividend; Halliburton alliance
Revenue $125.3M, down 2% sequentially, flat YoY; GAAP EPS $0.19, ex-items $0.22 (up 5% sequentially, 24% YoY).
Core Labs Q2 revenue $127.9M (+6% YoY); adj EPS $0.21 (+80% YoY); declares $0.01 dividend
Revenue $127.9M, flat QoQ, up 6% YoY; GAAP EPS $0.48 (incl. $11.6M tax benefit and $2.9M gains).
Core Laboratories terminates $60M ATM program; no shares sold under agreement
Terminated Equity Distribution Agreement dated June 9, 2022 with Wells Fargo and BofA.
Core Labs shareholders elect directors, approve KPMG, say-on-pay, director plan
Harvey Klingensmith and Curtis Anastasio elected as Class I directors with 33.6M and 37.3M votes for, respectively.
Core Labs issues $50M in senior secured notes at 7.25%-7.50% to refinance debt
$25M of 7.25% notes due 2028 and $25M of 7.50% notes due 2030 placed privately.
Core Laboratories completes redomestication from Netherlands to Delaware as Core Laboratories Inc.
Effective May 1, 2023, Core Lab N.V. merged into Core Lab Luxembourg and then redomesticated as Core Laboratories Inc. (Delaware).
On August 19, 2026, Kwaku Temeng verbally notified the Board of Directors of Core Laboratories Inc. (the “Company”) of his intention to resign as a director of the Company effective October 1, 2026.
Effective March 21, 2024, the Board approved the appointment of Mr. Sow Hang Teo to serve as the Company’s Vice President and Chief Accounting Officer.
On March 21, 2024, Mr. Kevin Daniels announced his intention to resign as Vice President and Chief Accounting Officer of Core Laboratories Inc. (the “Company”) to pursue other opportunities.
Max materiality 0.80 · Median 0.60 · Most common event earnings